TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.15), $0.05 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $22.6 million versus the consensus estimate of $21.89 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.